Emmune was founded to develop eCD4-Ig as a recombinant protein therapeutic for treating HIV infection, and to develop AAV-expressed eCD4-Ig as a one-time therapeutic intervention for life-long treatment and prevention of HIV infection. Recognizing that there may never be a safe and effective vaccine for HIV, AAV-expressed eCD4-Ig is the shortest path to vaccine-like immunity against HIV infection. Importantly for people already living with HIV, Emmune aims to functionally cure HIV with AAV-expressed eCD4-Ig. Prior to the availability of vectored approaches, Emmune will develop eCD4-Ig as a recombinant protein therapeutic for HIV treatment. Emmune seeks the broad application of its innovations on the AAV vector platform to other diseases.